Baird cuts Ultragenyx Pharma to Neutral, trims price target
Baird downgraded Ultragenyx Pharma to Neutral and cut its price target to $16.00 per share from $40.00, according to ratings actions reported by Benzinga.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.